Development of an Innovative Point-of-Care Screening Tool for Alzheimer's Disease

研究神经-希波坎普公司是一家私人临床研究机构，由过去20年来研究阿尔茨海默病的医生和研究人员组成。他们目前正在渥太华和加蒂诺的地点进行2b期和3期临床试验。已有研究表明，早期发现阿尔茨海默病可以提高治疗干预的效果和生活质量。因此，作为他们临床前计划的一部分，并与La Cité的两个研究中心合作，RNH旨在开发一种护理点诊断工具，在年轻的高危人群中非侵入性地检测与阿尔茨海默病相关的风险基因。设在La Cité的智能原型技术专业知识中心和生物创新技术获取中心拥有人员和专门设备方面的专业知识，以帮助RNH开展这项工作。

Recherches Neuro-Hippocampe Inc. is a private clinical research institution comprised of physicians and researchers studying Alzheimer's disease for the past 20 years. They are currently conducting Phase 2b and Phase 3 clinical trials at their Ottawa and Gatineau sites. It has been shown that early detection of Alzheimer's disease allows for improved efficacy of therapeutic interventions and quality of life. Therefore, as part of their preclinical program, and in collaboration with two research centers at La Cité, RNH aims to develop a point-of-care diagnostic tool to non-invasively detect risk genes associated with Alzheimer's disease in the younger at-risk population. The Centre for Expertise in Smart Prototyping, and the Technology Access Centre of Bio-Innovation, at La Cité have the expertise in personnel and specialized equipment to help RNH in their endeavor.